ASCENTAGE PH.GRP SP.ADR/4
ASCENTAGE PH.GRP SP.ADR/4
Share · US04390B1052 · AAPG · A40ZYR (XNMS)
Overview Financial Indicators
27,99 EUR
8,02 % 2,08 EUR
Frankfurt (XNAS) · Current prices and charts at MoneyPeak
12.06.2025 17:34

Current Prices from ASCENTAGE PH.GRP SP.ADR/4

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
AAPG
USD
12.06.2025 17:34
32,13 USD
29,75 USD
+8,02 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
7,56 % 14,03 % 27,87 % 61,21 % 55,24 % 60,28 % 66,85 %

Company Profile for ASCENTAGE PH.GRP SP.ADR/4 Share

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Company Data

Name ASCENTAGE PH.GRP SP.ADR/4
Company Ascentage Pharma Group International
Symbol AAPG
Website https://www.ascentage.cn
Primary Exchange XNMS Frankfurt
WKN A40ZYR
ISIN US04390B1052
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Dajun Yang M.D., Ph.D.
Market Capitalization 2 Mrd.
Country China
Currency EUR
Employees 0,6 T
Address Suzhou Industrial Park, 215000 Suzhou
IPO Date 2025-01-24

ID Changes

Date From To
27.01.2025 AAPGV AAPG

Ticker Symbols

Name Symbol
Frankfurt 36X0.F
NASDAQ AAPG

More Shares

Investors who ASCENTAGE PH.GRP SP.ADR/4 hold also have the following shares in their portfolio:
IA FINANCIAL CORP INC
IA FINANCIAL CORP INC Share
STATE STREET 22/33 FLR
STATE STREET 22/33 FLR Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025